Catheter Precision Announces That New Clinical Data From The VIVO EU Registry Was Presented Last Week At The Society Of Cardiac Robotic Navigation Meeting; 17 (≈95%) Patients Had Successful Ablation Procedures; 83% Of Patients Had No Recurrence Of The...

導管精準宣佈，VIVO歐洲註冊數據最新臨床數據已在上週在心臟機器人導航學會議上發佈；17（≈95%）名患者成功進行了消融手術；83%的患者未出現復發。

Benzinga · 11/04 08:42

Catheter Precision Announces That New Clinical Data From The VIVO EU Registry Was Presented Last Week At The Society Of Cardiac Robotic Navigation Meeting; 17 (≈95%) Patients Had Successful Ablation Procedures; 83% Of Patients Had No Recurrence Of The Arrhythmia At 12 Months Post Ablation

Cathter Precision宣佈，來自VIVO歐盟註冊機構的新臨床數據已於上週在心臟學會機器人導航會議上公佈；17名（約95％）名患者成功進行了消融手術；83％的患者在消融後的12個月內沒有心律失常復發

Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of Cardiac Robotic Navigation (SCRN) meeting in Lisbon, Portugal.

總部位於美國的創新醫療器械公司Catheter Precision, Inc.（紐約證券交易所代碼：VTAK）今天宣佈，來自VIVO歐盟註冊機構的新臨床數據已於上週在葡萄牙里斯本舉行的心臟機器人導航學會（SCRN）會議上公佈。

As previously announced, there were three presentations about VIVO during the SCRN meeting which took place October 28-29. The presentation by Professor Leonor Parreira shared the final data from Hospital da Luz. This center enrolled 27 subjects of which 18 proceeded with an ablation procedure with the following results:

正如先前宣佈的那樣，在10月28日至29日舉行的SCRN會議期間，有三場關於VIVO的演講。萊昂諾爾·帕雷拉教授的演講分享了達盧茲醫院的最終數據。該中心招收了27名受試者，其中18名接受了消融手術，結果如下：

100% accurate identification of the site of origin to the exact or neighboring cardiac segment

100% 準確識別確切或鄰近心臟段的起源部位

17 (≈95%) patients had successful ablation procedures

17 (≥ 95%) 名患者成功進行了消融手術

83% of patients had no recurrence of the arrhythmia at 12 months post ablation

83% 的患者在消融後 12 個月內沒有心律失常復發

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Catheter Precision Announces That New Clinical Data From The VIVO EU Registry Was Presented Last Week At The Society Of Cardiac Robotic Navigation Meeting; 17 (≈95%) Patients Had Successful Ablation Procedures; 83% Of Patients Had No Recurrence Of The...

Catheter Precision Announces That New Clinical Data From The VIVO EU Registry Was Presented Last Week At The Society Of Cardiac Robotic Navigation Meeting; 17 (≈95%) Patients Had Successful Ablation Procedures; 83% Of Patients Had No Recurrence Of The...

Catheter Precision Announces That New Clinical Data From The VIVO EU Registry Was Presented Last Week At The Society Of Cardiac Robotic Navigation Meeting; 17 (≈95%) Patients Had Successful Ablation Procedures; 83% Of Patients Had No Recurrence Of The Arrhythmia At 12 Months Post Ablation

Catheter Precision Announces That New Clinical Data From The VIVO EU Registry Was Presented Last Week At The Society Of Cardiac Robotic Navigation Meeting; 17 (≈95%) Patients Had Successful Ablation Procedures; 83% Of Patients Had No Recurrence Of The Arrhythmia At 12 Months Post Ablation

Cathter Precision宣佈，來自VIVO歐盟註冊機構的新臨床數據已於上週在心臟學會機器人導航會議上公佈；17名（約95％）名患者成功進行了消融手術；83％的患者在消融後的12個月內沒有心律失常復發

風險及免責聲明

聲明